EO4010 in Previously Treated Metastatic Colorectal Carcinoma (AUDREY)
A Global Multicenter Phase 1/2 Trial of EO4010, a Novel Microbial Derived Peptide Therapeutic Vaccine, in Combination With Nivolumab and/or Bevacizumab, for Treatment of Patients With Previously Treated Metastatic Colorectal Carcinoma
Sponsor: Enterome
Terminated
Sponsor decision to stop recruitment in context of overall EO4010 development goals. Stop of recruitment was not related to any safety concern, with the safety profile of EO4010 being benign
Other terminated trials from Enterome
- Adrenocortical Carcinoma · Phase PHASE1/PHASE2 · Oct 2024
- Colorectal Cancer · Phase PHASE2 · Jan 2024
- Crohn's Disease · Phase NA · Dec 2017
More terminations from Enterome
Other Colorectal Cancer Metastatic trials with similar outcome
This PHASE1/PHASE2 trial investigates Colorectal Cancer Metastatic and is currently terminated or withdrawn. Enterome leads this study, which shows 8 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
Status: Active Not Recruiting → Terminated
-
Nov 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
Aug 2023 — Nov 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Nov 2022 — Mar 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Enterome
For direct contact, visit the study record on ClinicalTrials.gov .